FRBRX: Franklin Biotechnology Discovery Fund - MutualFunds.com
Continue to site >
Trending ETFs

Welcome to MutualFunds.com

Please help us personalize your experience and select the one that best describes you.

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.
Not interested

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission

We hope you enjoy your experience

You have successfully subscribed to Advisor Access. Thank you!
Help us personalize your experience.
Which type of investor describes you best?
Help us personalize your experience.
What is your AUM?
Knowing your investable assets will help us build and prioritize features that will suit your investment needs.

Congratulations on personalizing your experience.

Email is verified. Thank you!

Franklin Biotechnology Discovery R6

FRBRX - Snapshot

Vitals

  • YTD Return -6.4%
  • 3 Yr Annualized Return 11.2%
  • 5 Yr Annualized Return 12.9%
  • Net Assets $1.42 B
  • Holdings in Top 10 41.9%

52 WEEK LOW AND HIGH

$169.22
$157.13
$207.30

Expenses

OPERATING RELATED FEES

  • Expense Ratio 0.66%

SALES FEES

  • Front Load N/A
  • Deferred Load N/A

BROKERAGE FEES

  • Turnover 47.30%

TRADING FEES

  • Max Redemption Fee N/A

Min Investment

  • Standard (Taxable) $1,000,000
  • IRA N/A

Fund Classification

Compare FRBRX to Popular Health Care Sector Equity Funds and ETFs

Overview

Income Profile

Income Risk

Returns Profile

Allocations

Expenses

About

Vanguard Health Care Fund

Fund

$237.03

+0.62%

$51.72 B

0.92%

$2.16

9.88%

0.32%

Health Care Select Sector SPDR® Fund

XLV | ETF

$131.48

+1.15%

$27.88 B

1.35%

$1.76

15.15%

0.12%

T. Rowe Price Health Sciences Fund

Fund

$110.46

+0.69%

$19.01 B

-

$0.00

11.75%

0.76%

Vanguard Health Care Index Fund

Fund

$127.81

+1.00%

$17.94 B

1.13%

$1.43

14.21%

0.10%

Vanguard Health Care Index Fund

VHT | ETF

$255.45

+0.98%

$17.94 B

1.13%

$2.85

13.30%

0.10%

FRBRX - Profile

Distributions

  • YTD Total Return -6.4%
  • 3 Yr Annualized Total Return 11.2%
  • 5 Yr Annualized Total Return 12.9%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -0.25%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Franklin Biotechnology Discovery Fund
  • Fund Family Name
    Franklin Templeton Investments
  • Inception Date
    May 01, 2013
  • Shares Outstanding
    98450
  • Share Class
    Retirement
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Evan McCulloch

FRBRX - Performance

Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD -6.4% -81.0% 31.0% 91.55%
1 Yr 10.0% -28.3% 121.6% 94.82%
3 Yr 11.2%* 6.8% 50.0% 87.84%
5 Yr 12.9%* 5.0% 42.5% 69.50%
10 Yr 15.5%* 9.3% 19.7% 49.59%

* Annualized

Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2020 14.7% -13.6% 178.2% 45.93%
2019 24.2% 3.8% 63.8% 29.66%
2018 -18.2% -49.7% 21.5% 89.05%
2017 16.6% -59.8% 54.4% 55.56%
2016 -20.6% -36.6% 11.6% 77.34%

Total Return Ranking - Trailing

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
YTD -6.4% -80.9% 31.0% 92.02%
1 Yr 10.0% -30.3% 121.6% 90.28%
3 Yr 11.2%* -14.1% 50.0% 84.18%
5 Yr 12.9%* -3.7% 42.5% 60.00%
10 Yr 15.5%* 9.3% 19.7% 44.70%

* Annualized

Total Return Ranking - Calendar

Period FRBRX Return Category Return Low Category Return High Rank in Category (%)
2020 14.7% -13.6% 178.2% 45.93%
2019 24.2% 3.8% 63.8% 29.66%
2018 -18.2% -25.3% 22.2% 90.51%
2017 19.3% -10.8% 54.4% 58.52%
2016 -16.8% -36.6% 11.6% 70.31%

NAV & Total Return History

FRBRX - Holdings

Concentration Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Assets 1.42 B 2.67 M 51.7 B 42.05%
Number of Holdings 112 11 506 29.74%
Net Assets in Top 10 595 M 2.19 K 19.3 B 29.74%
Weighting of Top 10 41.91% 7.2% 94.7% 37.93%

Top 10 Holdings

  1. Gilead Sciences Inc 6.74%
  2. Regeneron Pharmaceuticals Inc 6.06%
  3. Regeneron Pharmaceuticals Inc 6.06%
  4. Regeneron Pharmaceuticals Inc 6.06%
  5. Regeneron Pharmaceuticals Inc 6.06%
  6. Regeneron Pharmaceuticals Inc 6.06%
  7. Regeneron Pharmaceuticals Inc 6.06%
  8. Regeneron Pharmaceuticals Inc 6.06%
  9. Regeneron Pharmaceuticals Inc 6.06%
  10. Regeneron Pharmaceuticals Inc 6.06%

Asset Allocation

Weighting Return Low Return High FRBRX % Rank
Stocks 		98.95% 82.66% 104.58% 61.64%
Other 		0.53% -26.05% 9.11% 17.67%
Cash 		0.52% -0.13% 17.34% 37.07%
Preferred Stocks 		0.00% 0.00% 5.23% 56.47%
Convertible Bonds 		0.00% 0.00% 0.03% 52.59%
Bonds 		0.00% 0.00% 17.12% 55.60%

Stock Sector Breakdown

Weighting Return Low Return High FRBRX % Rank
Healthcare 		99.00% 62.01% 100.00% 63.79%
Financial Services 		1.00% 0.00% 2.61% 4.74%
Utilities 		0.00% 0.00% 0.83% 52.59%
Technology 		0.00% 0.00% 19.82% 57.76%
Real Estate 		0.00% 0.00% 6.19% 56.03%
Industrials 		0.00% 0.00% 6.41% 56.47%
Energy 		0.00% 0.00% 0.93% 52.59%
Communication Services 		0.00% 0.00% 8.10% 54.74%
Consumer Defense 		0.00% 0.00% 29.47% 56.90%
Consumer Cyclical 		0.00% 0.00% 18.45% 56.03%
Basic Materials 		0.00% 0.00% 8.53% 65.52%

Stock Geographic Breakdown

Weighting Return Low Return High FRBRX % Rank
US 		93.66% 56.42% 104.03% 23.71%
Non US 		5.29% 0.00% 40.85% 80.17%

FRBRX - Expenses

Operational Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.66% 0.08% 2.91% 56.83%
Management Fee 0.60% 0.00% 1.25% 36.36%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee 0.15% 0.03% 0.25% 78.05%

Sales Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

FRBRX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 47.30% 3.00% 256.00% 54.94%

FRBRX - Distributions

Dividend Yield Analysis

FRBRX Category Low Category High FRBRX % Rank
Dividend Yield 0.00% 0.00% 0.70% 57.33%

Dividend Distribution Analysis

FRBRX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Monthly Annually

Net Income Ratio Analysis

FRBRX Category Low Category High FRBRX % Rank
Net Income Ratio -0.25% -2.54% 1.92% 61.40%

Capital Gain Distribution Analysis

FRBRX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

FRBRX - Fund Manager Analysis

Managers

Evan McCulloch

Start Date

Tenure

Tenure Rank

Sep 15, 1997

23.81

23.8%

Mr. McCulloch, CFA, joined Franklin Templeton Investments in 1992.

Wendy Lam

Start Date

Tenure

Tenure Rank

Sep 01, 2018

2.83

2.8%

Ms. Lam has joined Franklin Templeton Investments in 2016. Prior to joining Franklin Templeton, Ms. Lam was an Executive Director and Senior Analyst covering large-cap biotechnology for Oppenheimer & Co and had been an Equity Research Associate at Bank of America Merrill Lynch, Morgan Stanley and Oppenheimer & Co. Ms. Lam has a Ph.D degree.

Akiva Felt

Start Date

Tenure

Tenure Rank

Jan 27, 2020

1.42

1.4%

Mr. Felt has been a portfolio manager, providing research and advice on the purchases and sales of individual securities and portfolio risk assessment. He joined Franklin Templeton in 2018. Prior to joining Franklin Templeton, Mr. Felt was a Senior Research Analyst with Asymmetry Capital, a healthcare focused hedge fund. He has covered the biotechnology sector since 2007 in increasing capacities on the sell-side, most recently as Managing Director for Oppenheimer & Co.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 23.81 6.75 1.21

Advertisement

×

Wait! Do you know all the important aspects of mutual funds?

×

Free Advisor Access newsletter emailed to you.

Receive free and exclusive email updates for financial advisors about best performers, news, CE accredited webcasts and more.

Sign up for Advisor Access

Receive email updates about best performers, news, CE accredited webcasts and more.

Disclaimer: By registering, you agree to share your data with MutualFunds.com and opt-in to receiving occasional communications about projects and events. The contents of this form are subject to the MutualFunds.com Privacy Policy. You can unsubscribe at any time.